Appendix A

|  |  |  |
| --- | --- | --- |
| **Measures Finalized in FY 2015 IPPS/LTCH** | | |
| **Measure Domain** | **NQF Endorsement Number** | **Measure Name** |
| Patient Safety | 0139 | Central Line-Associated Bloodstream Infection (CLABSI) |
| 0138 | Catheter-Associated Urinary Tract Infection (CAUTI) |
| 0753 | Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure |
| Cancer Specific Treatment | 0223 | Adjuvant Chemotherapy is considered or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer |
| 0559 | Combination Chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or Stage II or III hormone receptor negative breast cancer |
| 0220 | Adjuvant Hormonal Therapy |
| Improvement Project (SCIP)Surgical Care | 0218 | Surgery Patients who Received Appropriate VTE Prophylaxis within 24 Hrs Prior to Surgery to 24 Hrs After Surgery End Time |
| 0284 | Surgery Patients on Beta Blocker Therapy Prior to Admission who received a Beta Blocker during the Perioperative Period |
| 0453 | Urinary Catheter Removed on Post-Operative Day 1 or Post-Operative Day 2 with Day Surgery Being Day Zero |
| 0527 | Prophylactic Antibiotic Received Within 1 Hr Prior to Surgical Incision |
| 0528 | Prophylactic Antibiotic Selection for Surgical Patients |
| 0529 | Prophylactic Antibiotic Discontinued Within 24 Hrs After Surgery End Time |
| Oncology Care Measures | 0382 | Oncology-Radiation Dose Limits to Normal Tissues |
| 0383 | Oncology: Plan of Care for Pain |
| 0384 | Oncology: Pain Intensity Quantified |
| 0390 | Prostate Cancer-Adjuvant Hormonal Therapy for High-Risk Patients |
| 0389 | Prostate Cancer-Avoidance of Overuse Measure-Bone Scan for Staging Low-Risk Patients |
| 0166 | HCAHPS Patient Experience of Care Survey |
| Clinical Effectiveness | 1822 | External Beam Radiotherapy (EBRT) |